Fate Therapeutics Statistics
Want to see FATE full AI Analyst Report?
Fate Therapeutics (FATE) Stock Statistics & Valuation Metrics
Total Valuation
Fate Therapeutics has a market cap or net worth of $138.59M. The enterprise value is $228.43M.
- Market Cap
- $138.59M
- Enterprise Value
- $228.43M
Share Statistics
Fate Therapeutics has 121,568,756 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 121,568,756
- Owned by Insiders
- 12.24%
- Owned by Institutions
- 41.92%
Financial Efficiency
Fate Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -51.39%.
- Return on Equity (ROE)
- -0.66
- Return on Assets (ROA)
- -0.43
- Return on Invested Capital (ROIC)
- -51.39%
- Return on Capital Employed (ROCE)
- -0.52
- Revenue Per Employee
- 41.28K
- Profits Per Employee
- -846.68K
- Employee Count
- 161
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Fate Therapeutics is -1.09. Fate Therapeutics’s PEG ratio is -0.04.
- PE Ratio
- -1.09
- PS Ratio
- 27.48
- PB Ratio
- 1.04
- Price to FCF
- -1.22
- Price to Operating Cash Flow
- -1.31
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Fate Therapeutics had revenue of 6.65M and earned -136.31M in profits. Earnings per share was -1.15.
- Revenue
- 6.65M
- Gross Profit
- -6.25M
- Operating Income
- -147.70M
- Pretax Income
- -136.31M
- Net Income
- -136.31M
- EBITDA
- -127.02M
- Earnings Per Share (EPS)
- -1.15
Cash Flow
In the last 12 months, operating cash flow was -105.46M and capital expenditures -1.51M, giving a free cash flow of -106.97M billion.
- Operating Cash Flow
- -105.46M
- Free Cash Flow
- -106.97M
- Free Cash Flow per Share
- -0.87
Dividends & Yields
Fate Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -80.86%
- Earnings Yield
- -88.66%
Stock Price Statistics
- Beta
- 2.70
- 52-Week Price Change
- 18.26%
- 50-Day Moving Average
- 2.15
- 200-Day Moving Average
- 2.00
- Relative Strength Index (RSI)
- 20.88
- Average Volume (3m)
- 1.46M
Important Dates
Fate Therapeutics upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Fate Therapeutics as a current ratio of 5.79, with Debt / Equity ratio of 37.57%
- Current Ratio
- 5.79
- Quick Ratio
- 5.79
- Debt to Market Cap
- 0.63
- Net Debt to EBITDA
- -0.25
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Fate Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Fate Therapeutics EV to EBITDA ratio is -1.42, with an EV/FCF ratio of -1.52.
- EV to Sales
- 34.28
- EV to EBITDA
- -1.42
- EV to Free Cash Flow
- -1.52
- EV to Operating Cash Flow
- -1.54
Balance Sheet
Fate Therapeutics has $139.13M in cash and marketable securities with $74.49M in debt, giving a net cash position of $64.64M billion.
- Cash & Marketable Securities
- $139.13M
- Total Debt
- $74.49M
- Net Cash
- $64.64M
- Net Cash Per Share
- $0.53
- Tangible Book Value Per Share
- $1.08
Margins
Gross margin is -17.81%, with operating margin of -2760.04%, and net profit margin of -2619.64%.
- Gross Margin
- -17.81%
- Operating Margin
- -2760.04%
- Pretax Margin
- -2619.64%
- Net Profit Margin
- -2619.64%
- EBITDA Margin
- -2419.98%
- EBIT Margin
- -2657.62%
Analyst Forecast
The average price target for Fate Therapeutics is $5.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $5.13
- Price Target Upside
- 349.56% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- -33.45%
- EPS Growth Forecast
- 21.90%
Scores
- Smart Score
- 4
- AI Score
- 42

